Eradication of Helicobacter pylori can facilitate immune reconstitution in HIV-1-infected immunological non-responders

International Journal of Infectious Diseases

Volumn 14, Issue 4, 2010, Pages

  Magen, Eli ^a,b   Elbirt, Daniel ^a   Agmon Levin, Nancy ^a   Mishal, Joseph ^b   Sthoeger, Zev ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

^b BARZILAI MEDICAL CENTER   (Israel)

Author keywords

CD4; CD8; Eradication; Helicobacter pylori; HIV 1

Indexed keywords

AMOXICILLIN; CD4 ANTIGEN; CLARITHROMYCIN; EFAVIRENZ; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; OMEPRAZOLE; STAVUDINE; UREA; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CD8+ T LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; MALE; NONHUMAN; TREATMENT DURATION; UREA BREATH TEST; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BREATH TESTS; CD4 LYMPHOCYTE COUNT; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; RNA, VIRAL; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 77949485008     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.03.036     Document Type: Article

References (45)

1. Aiuti F., and Mezzaroma I. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. AIDS Rev 8 (2006) 88-97
2. Kaufmann G.R., Perrin L., Pantaleo G., Opravil M., Furrer H., Telenti A., et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 163 (2003) 2187-2195
3. D'Amico R., Yang Y., Mildvan D., Evans S.R., Schnizlein-Bick C.T., Hafner R., et al. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol 25 (2005) 106-115
4. Collazos J., Asensi V., Cartón J.A., and Grupo Español Para El Estudio Multifactorial De La Adherencia (GEEMA). Factors associated with poor immunologic responses despite viral suppression in markedly immunosuppressed patients. AIDS Patient Care STDS 21 (2007) 378-384
5. Vaamonde C.M., Hoover D.R., Anastos K., Tan T., Shi Q., Gao W., et al. Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women. AIDS Res Hum Retroviruses 22 (2006) 222-231
6. Battegay M., Nüesch R., Hirschel B., and Kaufmann G.R. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 6 (2006) 280-287
7. García F., Alonso M.M., Romeu J., Knobel H., Arrizabalaga J., Ferrer E., et al. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study. J Acquir Immune Defic Syndr 25 (2000) 26-35
8. Marchetti G., Meroni L., Varchetta S., Terzieva V., Bandera A., Manganaro D., et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis 186 (2002) 606-616
9. Goicoechea M., Smith D.M., Liu L., May S., Tenorio A.R., Ignacio C.C., et al. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 194 (2006) 29-37
10. Eggena M.P., Barugahare B., Okello M., Mutyala S., Jones N., Ma Y., et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis 191 (2005) 694-701
11. Borkow G., Leng Q., Weisman Z., Stein M., Galai N., Kalinkovich A., et al. Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. J Clin Invest 106 (2000) 1053-1060
12. Wilson K.T., and Crabtree J.E. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 133 (2007) 288-308
13. Velin D., and Michetti P. Immunology of Helicobacter pylori infection. Digestion 73 (2006) 116-123
14. Fabris P., Bozzola L., Benedetti P., Scagnelli M., Nicolin R., Manfrin V., et al. H. pylori infection in HIV-positive patients. A serohistological study. Dig Dis Sci 42 (1997) 289-292
15. Lionetti P., Amarri S., Silenzi F., Galli L., Cellini M., de Martino M., et al. Prevalence of Helicobacter pylori infection detected by serology and 13C-urea breath test in HIV-1 perinatally infected children. J Pediatr Gastroenterol Nutr 28 (1999) 301-306
16. Cacciarelli A.G., Marano Jr. B.J., Gualtieri N.M., Zuretti A.R., Torres R.A., Starpoli A.A., et al. Lower Helicobacter pylori infection and peptic ulcer disease prevalence in patients with AIDS and suppressed CD4 counts. Am J Gastroenterol 91 (1996) 1783-1784
17. Vaira D., Miglioli M., Menegatti M., Holton J., Boschini A., Vergura M., et al. Helicobacter pylori status, endoscopic findings, and serology in HIV-1-positive patients. Dig Dis Sci 40 (1995) 1622-1626
18. Edwards P.D., Carrick J., Turner J., Lee A., Mitchell H., and Cooper D.A. Helicobacter pylori-associated gastritis is rare in AIDS: antibiotic effect or a consequence of immunodeficiency?. Am J Gastroenterol 86 (1991) 1761-1764
19. Marano Jr. B.J., Smith F., and Bonanno C.A. Helicobacter pylori prevalence in acquired immunodeficiency syndrome. Am J Gastroenterol 88 (1993) 687-690
20. Moges F., Kassu A., Mengistu G., Adugna S., Andualem B., Nishikawa T., et al. Seroprevalence of Helicobacter pylori in dyspeptic patients and its relationship with HIV infection, ABO blood groups and life style in a university hospital, northwest Ethiopia. World J Gastroenterol 12 (2006) 1957-1961
21. Lichterfeld M., Lorenz C., Nischalke H.D., Scheurlen C., Sauerbruch T., and Rockstroh J.K. Decreased prevalence of Helicobacter pylori infection in HIV patients with AIDS defining diseases. Z Gastroenterol 40 (2002) 11-14
22. AliMohamed F., Lule G.N., Nyong'o A., Bwayo J., and Rana F.S. Prevalence of Helicobacter pylori and endoscopic findings in HIV seropositive patients with upper gastrointestinal tract symptoms at Kenyatta National Hospital, Nairobi. East Afr Med J 79 (2002) 226-231
23. Siliciano J.D., and Siliciano R.F. Latency and viral persistence in HIV-1 infection. J Clin Invest 106 (2000) 823-825
24. Stebbing J., Gazzard B., and Douek D.C. Where does HIV live?. N Engl J Med 350 (2004) 1872-1880
25. Krauss-Etschmann S., Sammler E., Koletzko S., Konstantopoulos N., Aust D., Gebert B., et al. Chemokine receptor 5 expression in gastric mucosa of Helicobacter pylori-infected and noninfected children. Clin Diagn Lab Immunol 10 (2003) 22-29
26. Sommer F., Faller G., Konturek P., Kirchner T., Hahn E.G., Zeus J., et al. Antrum- and corpus mucosa-infiltrating CD4+ lymphocytes in Helicobacter pylori gastritis display a Th1 phenotype. Infect Immun 66 (1998) 5543-5546
27. Agace W.W., Roberts A.I., Wu L., Greineder C., Ebert E.C., and Parker C.M. Human intestinal lamina propria and intraepithelial lymphocytes express receptors specific for chemokines induced by inflammation. Eur J Immunol 30 (2000) 819-826
28. Orenstein J.M., Fox C., and Wahl S.M. Macrophages as a source of HIV during opportunistic infections. Science 276 (1997) 1857-1861
29. O'Brien W.A., Grovit-Ferbas K., Namizi A., Zhao J.Q., Diagne A., Idler K., et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86 (1995) 1082-1089
30. Iellem A., Mariani M., Lang R., Recalde H., Panina-Bordignon P., Sinigaglia F., et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 194 (2001) 847-853
31. Strömberg E., Lundgren A., Edebo A., Lundin S., Svennerholm A.M., and Lindholm C. Increased frequency of activated T-cells in the Helicobacter pylori-infected antrum and duodenum. FEMS Immunol Med Microbiol 36 (2003) 159-168
32. Korin Y.D., and Zack J.A. Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J Virol 73 (1999) 6526-6532
33. Staprans S.I., Hamilton B.L., Follansbee S.E., Elbeik T., Barbosa P., Grant R.M., et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 182 (1995) 1727-1737
34. Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387 (1997) 183-188
35. Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387 (1997) 188-191
36. Fabris P., Pilotto A., Bozzola L., Tositti G., Soffiati G., Manfrin V., et al. Serum pepsinogen and gastrin levels in HIV-positive patients: relationship with CD4+ cell count and Helicobacter pylori infection. Aliment Pharmacol Ther 16 (2002) 807-811
37. Gebert B., Fischer W., Weiss E., Hoffmann R., and Haas R. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 301 (2003) 1099-1102
38. Oswald-Richter K., Torres V.J., Sundrud M.S., VanCompernolle S.E., Cover T.L., and Unutmaz D. Helicobacter pylori VacA toxin inhibits human immunodeficiency virus infection of primary human T cells. J Virol 80 (2006) 11767-11775
39. Shirai M., Fujinaga R., Masaki T., and Berzofsky J.A. Impaired development of HIV-1 gp160-specific CD8(+) cytotoxic T cells by a delayed switch from Th1 to Th2 cytokine phenotype in mice with Helicobacter pylori infection. Eur J Immunol 31 (2001) 516-526
40. Steffens C.M., Managlia E.Z., Landay A., and Al-Harthi L. Interleukin-7-treated naive T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood 99 (2002) 3310-3318
41. Unutmaz D., KewalRamani V.N., Marmon S., and Littman D.R. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med 189 (1999) 1735-1746
42. Sundrud M.S., Torres V.J., Unutmaz D., and Cover T.L. Inhibition of primary human T cell proliferation by Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion. Proc Natl Acad Sci U S A 101 (2004) 7727-7732
43. Shelton M.J., Akbari B., Hewitt R.G., Adams J.M., and Morse G.D. Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIV-positive patients. J Acquir Immune Defic Syndr 24 (2000) 79-82
44. Brenchley J.M., Price D.A., Schacker T.W., Asher T.E., Silvestri G., Rao S., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12 (2006) 1365-1371
45. Tamaoki J., Kadota J., and Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 117 Suppl 9A (2004) 5S-11S